(Q36780663)

English

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

scientific article published on November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

Europe PubMed Central

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

systematic review

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Noble

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

P M Ellis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

J A Mackay

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

W K Evans

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1042-1058

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of adjusting for censoring on meta-analyses of time-to-event outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Active-control equivalence trials and antihypertensive agents

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931641-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1556-0864(15)31641-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409993%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36780663&oldid=1635507474"